Abstract
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
MeSH terms
-
Fallopian Tube Neoplasms* / diagnosis
-
Fallopian Tube Neoplasms* / pathology
-
Fallopian Tube Neoplasms* / therapy
-
Female
-
Humans
-
Medical Oncology / methods
-
Medical Oncology / standards
-
Neoplasm Staging
-
Ovarian Neoplasms* / diagnosis
-
Ovarian Neoplasms* / pathology
-
Ovarian Neoplasms* / therapy
-
Peritoneal Neoplasms* / diagnosis
-
Peritoneal Neoplasms* / therapy
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Substances
-
Poly(ADP-ribose) Polymerase Inhibitors